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OBJECTIVES This study was designed to compare the three-year survival after percutaneous coronary
intervention (PCI) or coronary artery bypass graft surgery (CABG) in physician-directed and
patient-choice registries with the Angina With Extremely Serious Operative Mortality
Evaluation (AWESOME) randomized trial results.
BACKGROUND The AWESOME multicenter randomized trial and registry compared the long-term survival
after PCI and CABG for the treatment of patients with medically refractory myocardial
ischemia and at least one additional risk factor for adverse outcome with CABG. The
randomized trial demonstrated comparable three-year survival.
METHODS Over a five-year period (1995 to 2000), 2,431 patients with medically refractory myocardial
ischemia and at least one of five risk factors (prior heart surgery, myocardial infarction within
seven days, left ventricular ejection fraction 0.35, age 70 years, intra-aortic balloon
required to stabilize) were identified. By physician consensus, 1,650 patients formed a
physician-directed registry assigned to CABG (692), PCI (651) or further medical therapy
(307), and 781 were angiographically eligible for random allocation; 454 of these patients
constitute the randomized trial, and the remaining 327 constitute a patient choice registry.
Survival for CABG and PCI was compared using Kaplan-Meier curves and log-rank tests.
RESULTS The CABG and PCI 36-month survival rates for randomized patients were 79% and 80%,
respectively. The CABG and PCI 36-month survival rates were both 76% for the physician-
directed subgroup; comparable survival rates for the patient-choice subgroup were 80% and 89%,
respectively. None of the global log-rank tests for survival demonstrated significant differences.
CONCLUSIONS Both registries support the randomized trial conclusion: PCI is an alternative to CABG for
some medically refractory high-risk patients. (J Am Coll Cardiol 2002;39:266–73) © 2002
by the American College of Cardiology
Randomized clinical trials comparing percutaneous coro-
nary intervention (PCI) with coronary artery bypass graft
surgery (CABG) have demonstrated comparable long-term
survival (1–13). In most trials, relief of angina has been
comparable or slightly better with CABG, and the need for
further revascularization has favored CABG (1–11). Argen-
tine Randomized Trial of Percutaneous Transluminal Cor-
onary Angioplasty Versus Coronary Artery Bypass Surgery
in Multivessel Disease (ERACI) II has extended the pre-
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vious PCI versus CABG trials by including the use of stents
to treat patients with multivessel disease, the majority of
whom had unstable coronary syndromes (10). The recently
reported ARTS (Arterial Revascularization Therapies
Study) trial also included modern stents and compared
quality of life and cost of care end points (11,12).
The 1999 American College of Cardiology/American
Heart Association (ACC/AHA) Guidelines for Coronary
Artery Bypass Graft Surgery and the editorial that accom-
panied the publication of ERACI II specified that patient
groups with prior CABG, left ventricular ejection fraction
0.35, myocardial infarction (MI) within seven days or
intra-aortic balloon pump required to stabilize had not been
included in randomized comparisons of CABG and PCI
(13,14). These patient groups were not included in ARTS
either (11,12). A recently concluded randomized clinical
trial, Angina With Extremely Serious Operative Mortality
Evaluation (AWESOME), compared CABG and PCI
survival among patients with medically refractory ischemia
and these risk factors (15,16). AWESOME also included
the use of stents and glycoprotein IIb/IIIa receptor-blocking
drugs (15,16). The AWESOME trial demonstrated com-
parable three-year survival for the PCI and CABG groups
(16).
The principal purpose of random allocation of subjects is
the avoidance of known and unknown selection biases and
the avoidance of confounding that would result in noncom-
parable patient sets assigned to the alternative therapy arms
of the study. Randomization should result in a balanced
distribution of baseline variables in the alternative therapy
arms of the study. The reality of randomized clinical trials is
that many health care providers, patients and families do not
consent to random allocation, because they do not perceive
the alternative therapies to be equally effective. A prospec-
tive study of the eligible patients who were directed by
physicians not to participate, and of patients deemed ac-
ceptable but who declined random allocation, can reveal the
extent to which selection bias may obscure treatment dif-
ferences (17). Registry results also provide insight into
current medical decision making (18). This article compares
CABG and PCI survival in the AWESOME physician-
directed and patient-choice registries to survival in the
randomized clinical trial (15,16).
METHODS
The AWESOME protocol, baseline characteristics of ran-
domized patients and three-year outcomes of the random-
ized cohort have been reported (15,16). The AWESOME
trial was a nationwide, prospective randomized clinical trial
designed to compare long-term survival with CABG versus
PCI for patients with medically refractory myocardial isch-
emia and increased risk of adverse outcomes with CABG.
Patients were enrolled at 16 Veterans Affairs medical
centers over a five-year period (1995 to 2000). All 16 sites’
institutional review boards and the national VA Human
Abbreviations and Acronyms
ACC/AHA  American College of
Cardiology/American Heart Association
class of lesion grading
AWESOME  Angina With Extremely Serious
Operative Mortality Evaluation
CABG  coronary artery bypass graft surgery
CAD  coronary artery disease
IABP  intra-aortic balloon pump
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Association class of
heart failure
PCI  percutaneous coronary intervention (may
include stents or atherectomy, in
addition or in place of balloon
angioplasty only)
SVG  saphenous vein graft
TIMI  Thrombolysis In Myocardial Infarction
VA  U.S. Department of Veterans Affairs
Table 1. Baseline Comparisons of Randomized, Total Registry,
Physician-Directed and Patient-Choice Cohorts
Variable Random Registry
Physician-
Directed
Patient-
Choice
Patients number 454 1,977 1,650 327
Age mean 67 67 68 67
Age  70 years % 52 53 53 52
Prior PCI % 23 24 24 23
Prior CABG % 31 42* 44 36†
Prior MI % 57 57 57 59
MI 7 days % 33 32 31 39†
LVEF 0.35 % 21 18 18 16
LVEF mean 42 44 43 46
IABP % 2 5 5 3
Smoker % 35 30 30 35
Diabetes % 33 33 34 28
Hypertension % 70 67 68 64
Prior CHF % 61 69 71 57‡
Prior stroke % 13 12 12 9
Aspirin % 94 96 96 95
Heparin % 84 84 82 90
Beta-blocker % 79 78 78 77
Ca-blocker % 33 37 37 33
One-vessel % 18 22 20 30
Two-vessel % 41 33 33 37
Three-vessel % 41 44 47 33‡
Native CAD % 99 98 98 97
Graft CAD % 26 33* 35 26‡
LAD 70% % 89 83 83 83
L main 50% % 7 18* 19 12‡
ACC/AHA class C % 75 78 80 67‡
NYHA class III/IV % 61 69* 71 57‡
*Statistically significant difference between random and registry: p  0.01; †statisti-
cally significant difference between physician-directed and patient-choice registry
subsets: p  0.05; ‡statistically significant difference between physician-directed and
patient-choice registry subsets: p  0.01.
ACC/AHA classAmerican College of Cardiology/American Heart Association
coronary angiographic lesion classification; CABG coronary artery bypass graft; Ca
blocker  calcium channel blocking agent; CAD  coronary artery disease; CHF 
congestive heart failure; IABP  intra-aortic balloon pump; LVEF  left ventricular
ejection fraction; L main  left main stenosis; LAD  left anterior descending;
Native CAD  native vessel coronary artery disease; NYHA  New York Heart
Association; PCI  percutaneous coronary intervention.
267JACC Vol. 39, No. 2, 2002 Morrison et al.
January 16, 2002:266–73 PCI Versus CABG in High-Risk Unstable Angina
Rights Committee approved the protocol. The conduct of
the trial was reviewed annually by these committees.
A total of 22,662 patients were screened, and of these
patients, 7,278 did not meet criteria for myocardial isch-
emia, 5,783 failed to meet criteria for medically refractory
myocardial ischemia, and 10,030 had none of the risk
factors for adverse outcome with CABG. There were 2,431
clinically eligible patients who met all three clinical criteria.
After coronary angiography had been reviewed by both an
interventional cardiologist and a surgeon, a total of 781
patients (32%) were acceptable to both operators as candi-
dates for random allocation of revascularization method.
These patients were approached for informed consent, and
454 (58%) consented to a randomized choice of revascular-
ization. The 327 patients who refused random allocation
elected either CABG or PCI for themselves and are referred
to as the patient-choice registry. The 1,650 patients for
whom physician consensus would not allow random assign-
ment constitutes a prospective physician-directed registry:
692 were assigned to CABG, 651 were assigned to PCI,
and 307 were assigned further medical therapy.
Statistical analysis. Differences in baseline variable fre-
quencies were tested by chi-square tests for proportions.
Long-term survival was measured by Kaplan-Meier survival
estimates, which were plotted. The statistical significance of
global differences between survival curves was judged by
log-rank tests. Differences between CABG and PCI 36-
month survival were computed along with z-tests of the
differences.
RESULTS
In the entire registry, 83% (1,645/1,977) of patients were
revascularized during their index hospitalization. Among
those revascularized, 48% (n  787) received CABG and
52% (n  858) received PCI. Among physician-directed
patients 81% (n  1,343) were revascularized, 52% (n 
692) by CABG and 48% (n  651) by PCI. The difference
between these two rates is not statistically significant (chi-
square; p  0.10). Among patient-choice patients, 92%
(n  302) were revascularized, 31% (n  95) selected
CABG, and 69% (n  207) selected PCI. The difference
between these two rates is statistically significant (chi-
square; p  0.001).
Methods for CABG and PCI evolved over the course of
the study. Left internal mammary artery use increased from
57% in 1995 to 78% by study end, with an overall average of
70%. Stent use increased from 26% of PCI cases in 1995 to
89% in 1999, with an overall average use of 55%. As stent
use increased, directional and extractional atherectomy use
virtually disappeared. Intra-aortic balloon counter-pulsation
declined from 26% in 1995 to 11% in 1999, with an overall
use of supportive counter-pulsation of 22%.
Table 1 displays baseline comparisons of randomized and
registry patients. The overall registry profile is similar to the
randomized profile except for four baseline factors (prior
CABG, saphenous vein graft coronary artery disease [SVG
Table 2. Baseline Clinical and Angiographic Variables of
Physician-Directed and Patient-Choice Cohorts by Intervention
Physician-Directed Patient-Choice
CABG PCI CABG PCI
Patients n 692 651 95 207
Age years 69 66 68 66
Age  70 years % 63 42* 58 50
Prior PCI % 17 32* 17 26
Prior CABG % 22 55* 34 36
Prior MI % 51 65* 54 61
MI 7 day % 28 35* 36 41
LVEF 0.35 % 17 19 21 14
LVEF mean 43 43 45 46
IABP % 5 7 3 3
Smoker % 28 32 33 36
Diabetes % 36 31 22 32
Hypertension % 69 66 66 64
Prior CHF % 83 57* 47 60†
Prior stroke % 11 11 7 9
Three-vessel % 57 39* 35 30
Native CAD % 98 98 97 98
SVG CAD % 21 40* 20 26
LAD 70% % 92 78* 86 80
L main 50% % 34 11* 15 10
TIMI no flow % 44 54*† 51 37
ACC/AHA class C % 84 75* 57 70†
NYHA class III/IV % 83 57* 47 60†
*Statistically significant difference between CABG and PCI: p 0.01; †statistically
significant difference between CABG and PCI: p  0.05.
CABG  coronary artery bypass graft; SVG CAD  disease in saphenous vein
graft; TIMI no flow Thrombolysis In Myocardial Infarction trials class of occlusion
with no antegrade flow; PCI  percutaneous coronary intervention. Other abbrevi-
ations as in Table 1.
Table 3. The Percentage Allocation to CABG Among
Physician-Directed and Patient-Choice Patients by High-Risk
Baseline Subsets
Baseline Subset Physician-Directed Patient-Choice
Overall CABG allocation % 52 31
Age  70 years % 61* 35
Prior PCI % 36* 23
Prior CABG % 30* 30
Prior MI % 45* 29
MI 7 days % 46* 29
LVEF 0.35 % 49 41
IABP % 43 31
Smoker % 48 30
Diabetes % 55 24
Hypertension % 53 32
Prior CHF % 60* 26†
Prior stroke % 51 27
Three-vessel % 61* 35
LAD 70 % 56* 33
L main 50 % 77* 41
Native CAD % 52 31
SVG CAD % 36* 26
TIMI no flow % 46 39
ACC/AHA class C % 54* 27†
NYHA class III/IV % 60* 26†
Statistically significant difference between overall and risk group percent allocation to
CABG: *p  0.01; †p  0.05.
SVG CAD  disease in saphenous vein graft; TIMI no flow  Thrombolysis In
Myocardial Infarction trials classification of no antegrade flow with occluded vessel.
Other abbreviations as in Table 1.
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CAD], left main 50% and New York Heart Association
[NYHA] class III/IV).
Table 2 displays baseline prevalence rates and means of
clinical and angiographic risk factors in the two registry
subgroups allocated to CABG or PCI. Physician-directed
patients allocated to CABG had substantially higher prev-
alence rates for age70 years, prior congestive heart failure,
three-vessel disease, left anterior descending coronary artery
70%, left main 50%, ACC/AHA class C and NYHA
class III/IV compared with the rates for those allocated to
PCI. Physician-directed patients assigned to PCI had sub-
stantially higher prevalence rates for prior PCI, prior
CABG, SVG CAD, Thrombolysis in Myocardial Infarc-
tion (TIMI) no flow and prior MI compared with the
prevalence rates for those allocated to CABG.
Table 3 presents the percentage of patients allocated to
CABG by risk factors for the physician-directed and the
patient-choice subsets. Among physician-directed patients,
five risk factors (prior PCI, prior CABG, prior MI, MI 7
days and SVG CAD) are associated with a physician
preference for PCI and five risk factors (age70 years; prior
CHF, three-vessel disease, left main 50% and NYHA
class III/IV) are associated with a physician preference for
CABG. Single-vessel patients were preferentially directed
to PCI; patients with two-vessel disease were split compa-
rably between CABG and PCI. The differences between
these rates and the overall CABG allocation rate for
physician-directed patients are statistically significant.
Table 4 presents Kaplan-Meier estimates of CABG and
PCI: 36-month survival, 36-month survival free of unstable
angina and 36-month survival free of unstable angina or
repeat revascularization for the randomized patients and the
physician-directed and patient-choice registry subgroups.
The table lists CABG-PCI 36-month survival differences
and the standard errors of the differences. None of the
36-month survival differences is statistically significant.
Kaplan-Meier estimates of CABG and PCI survival,
survival free of unstable angina and survival free of unstable
angina or repeat revascularizations for the physician-
directed and patient-choice registries are shown in Figures 1
to 6 along with the global log-rank test. The yearly number
of patients with CABG and PCI and the yearly survival
estimates appear at the bottom of each plot. The CABG
and PCI plots appear parallel post six-months for all traits.
The in-hospital stroke rates for CABG and PCI were 1%
Table 4. CABG and PCI 36-Month Survival, Survival Free of
Unstable Angina and Survival Free of Unstable Angina or
Repeat Revascularizations
Outcome CABG PCI
CABG-
PCI
Difference
Standard
Error
Survival
Randomized 79% 80% –1% 5.6%
Physician-directed 76% 76% 0% 2.8%
Patient-choice 80% 89% –9% 5.9%
Survival free of unstable angina
Randomized 65% 59% 6% 8.4%
Physician-directed 66% 51% 15%* 5.0%
Patient-choice 63% 64% –1% 11%
Survival free of unstable angina
or repeat revascularization
Randomized 61% 48% 13% 10%
Physician-directed 63% 46% 17% 12%
Patient-choice 60% 57% 3% 5%
*Statistically significant difference p  0.01.
CABG coronary artery bypass graft; PCI percutaneous coronary intervention.
Figure 1. Kaplan-Meier plots of survival for coronary artery bypass graft surgery (CABG) (circle) versus percutaneous coronary intervention (PCI) () in
physician-directed registry. Numbers of patients and survival are given at the bottom.
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and 1%, respectively, in the randomized cohort, 3% and
0.3%, respectively, (p  0.01) in the physician-directed
registry and 5% and 1%, respectively, (NS) in the patient-
choice registry.
DISCUSSION
The AWESOME registry results extend the randomized
trial conclusion that CABG and PCI are both options for
medically refractory patients with angina having prior
CABG, recent MI, poor left ventricular function, age 70
or instability necessitating intra-aortic balloon counterpul-
sation (IABP) (15,16). The randomized cohort plus the two
registries include 100% of the patients who met all three
pre-established clinical criteria for the trial at the partici-
pating sites. Survival patterns for CABG and PCI are
similar in the randomized cohort and in both registry
cohorts. Survival free of repeat angina episodes is lower in
the PCI patients in the physician-directed registry but not
the patient-choice registry; the differences are not large and
Figure 2. Kaplan-Meier plots of survival for coronary artery bypass graft surgery (CABG) (circle) versus percutaneous coronary intervention (PCI) () in
patient-choice registry. Numbers of patients and survival are given at the bottom.
Figure 3. Kaplan-Meier plots of survival free of unstable angina for coronary artery bypass graft surgery (CABG) (circle) versus percutaneous coronary
intervention (PCI) () in physician-directed registry. Numbers of patients and survival are given at the bottom.
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occur in the first six months. The physician-directed and
patient-choice registry cohorts display the current attitudes
of physicians and patients as to the appropriate choice of
revascularization for high-risk patient subsets.
Physician direction. The prospectively gathered registry of
patients for whom physicians would not permit random
allocation provides some insight into factors associated with
the choice of revascularization. Five clinical factors (older
age, three-vessel disease, left main disease, NYHA class
III/IV and proximal left anterior descending disease) appear
to have influenced the physicians to direct patients toward
CABG. Patients with single-vessel disease were preferen-
tially directed to PCI, whereas patients with two-vessel
disease were split comparably.
The risk factors of prior MI, prior CABG, prior PCI and
SVG CAD were all associated with physician direction to
PCI. The conventional risk factors of smoking, hyperten-
sion, low left ventricular ejection fraction (LVEF 0.35) or
Figure 4. Kaplan-Meier plots of survival free of unstable angina for coronary artery bypass graft surgery (CABG) (circle) versus percutaneous coronary
intervention (PCI) () in patient-choice registry. Numbers of patients and survival are given at the bottom.
Figure 5. Kaplan-Meier plots of survival free of unstable angina and repeat revascularization for coronary artery bypass graft surgery (CABG) (circle) versus
percutaneous coronary intervention (PCI) () in physician-directed registry. Numbers of patients and survival are given at the bottom.
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a requirement for IABP do not appear to have been used to
preferentially direct patients to CABG or PCI. We are not
aware of published data from any other study that has
compared CABG to PCI for several of these important
high-risk subgroups, such as patients with prior CABG or
patients with very low LVEF (13–16). Nonetheless, physi-
cians often must choose a course of action when trial-based
guidelines do not exist.
Patient choice. The registry patients deemed acceptable
for both CABG and PCI by their respective operators (and
often referring physicians) are inherently lower risk than the
physician-directed cohort. These patients provide insight
into the factors associated with “patient choice.” With the
profusion of medical information available via the Internet,
television and radio, patient choice often includes some
physician direction. The majority of these patients chose
PCI.
Time trends in revascularization methodology. During
the five years of the study, the use by our surgeons of left and
right internal mammary arteries and radial arteries in-
creased, perhaps reflecting increased comfort with high-risk
cases. During the same period, stent and glycoprotein
IIb/IIIa blocker usage sharply increased in the study. As
stent use increased, atherectomy (all three types) use de-
creased; indeed, both directional and transluminal extrac-
tion catheter use nearly disappeared. Thus, this trial reflects
the continuous evolution of CABG and PCI revasculariza-
tion techniques during the period from 1995 to 2000.
Limitations. The first limitation of any registry is that
physician and patient selection is biased selection. Accord-
ingly, the registry provides a look at the systematic (non-
random) thinking of physicians and patients. Neither stroke
nor MI was systematically evaluated as an end point in a
blinded or core-laboratory controlled fashion. The 1,977-
patient registry is comparable in size to the BARI registry
(although the randomized trial is smaller), but not nearly as
large as such registries as the Veterans Affairs Continuous
Improvement program in cardiac surgery (17–22). There
were few women in the randomized trial or in the registry.
Summary and implications. The registry data extend the
results of the AWESOME randomized trial, suggesting
that PCI or CABG may relieve medically refractory isch-
emia among patients with risk factors for adverse outcomes
with CABG. The preferences for CABG or PCI within
high-risk subgroups reflect an overall weighing of the
different benefits and risks associated with CABG or PCI
on the part of the physicians and/or patients.
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